Inclusion Criteria:

- Histologically confirmed carcinoid tumor

- Metastatic or unresectable local-regional disease

- Measurable disease

- No osseous metastasis as the only site of disease

- No history or clinical evidence of CNS disease (e.g., primary brain tumor or any
brain metastasis)

- Performance status - Zubrod 0-2

- Performance status - Karnofsky 70-100%

- At least 12 weeks

- See Immunologic

- Absolute granulocyte count > 1,500/mm^3

- Platelet count > 100,000/mm^3

- Hemoglobin > 8 g/dL

- No bleeding diathesis or coagulopathy

- No hemoglobinopathies (e.g., thalassemia) or any other cause of hemolytic anemia

- Bilirubin < 1.5 mg/dL

- INR < 1.5 (if receiving warfarin)

- No evidence of decompensated liver disease (e.g., ascites, bleeding varices, or
spontaneous encephalopathy)

- Creatinine < 1.5 mg/dL

- No baseline proteinuria

- Patients with proteinuria (≥ 2+ or ≥ 100 mg/dL on urinalysis) are allowed
provided 24-hour urinary protein is < 500 mg

- No New York Heart Association grade II-IV congestive heart failure

- No serious cardiac arrhythmia requiring medication

- No clinically significant peripheral vascular disease

- No history of stroke

- None of the following within the past 6 months:

- Uncontrolled hypertension

- Transient ischemic attack

- Cerebrovascular accident

- Unstable angina

- Myocardial infarction

- No chronic pulmonary disease (e.g., chronic obstructive pulmonary disease)

- No documented pulmonary hypertension

- None of the following immunologically mediated diseases:

- Inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)

- Rheumatoid arthritis

- Idiopathic thrombocytopenia purpura

- Systemic lupus erythematosus

- Autoimmune hemolytic anemia

- Scleroderma

- Severe psoriasis

- No serious concurrent infections

- No active infection requiring parental antibiotics on day 0

- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant
human antibodies

- No known hypersensitivity to interferon alfa or to any excipient or vehicle included
in its formulation or delivery system

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No significant traumatic injury within the past 4 weeks

- No preexisting thyroid abnormality for which thyroid function can not be normalized
by medication

- No concurrent nonmalignant uncontrolled medical illness or one whose control may be
jeopardized by the complications of this study therapy

- No uncontrolled psychiatric disorder

- No psychiatric disorders that would preclude study compliance

- No other malignancy within the past 5 years except nonmelanoma skin cancer or
carcinoma in situ of the cervix

- No serious nonhealing wound ulcer or bone fracture

- No seizures not controlled with standard medical therapy

- Prior immunotherapy allowed

- No prior interferon

- No concurrent immunotherapy

- At least 4 weeks since prior chemotherapy, including radiosensitizers

- No more than 1 prior chemotherapy regimen, including radiosensitizers

- No concurrent chemotherapy

- At least 4 weeks since prior radiotherapy

- Prior radiotherapy must not have contained the single evaluable lesion of this
study in a radiation field

- No concurrent radiotherapy

- At least 4 weeks since prior major surgery or open biopsy (1 week for minor surgery)
and recovered

- No concurrent or recent full-dose anticoagulants or thrombolytic agents (except as
required to maintain patency of preexisting, permanent indwelling IV catheters)

- No concurrent chronic daily aspirin (more than 325 mg/day) or nonsteroidal
anti-inflammatory medications known to inhibit platelet function